What is Biogennix?
Biogennix operates at the intersection of material science and regenerative medicine, specializing in the development of advanced synthetic bone graft products. By leveraging its proprietary TrelCor technology, the company provides surgeons with high-performance tools such as the osteoSPAN Fusion Kits, Morpheus Moldable, and the Agilon product line. These offerings are engineered to optimize bone formation and improve clinical outcomes in complex orthopedic and spine surgery procedures. Through a commitment to biological innovation, Biogennix has established itself as a key player in the osteobiologics market, consistently delivering high-quality, specialized solutions that address the evolving needs of modern surgical practices.
How much funding has Biogennix raised?
Biogennix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Biogennix
PPP
Public-Private Partnership
What's next for Biogennix?
With the successful acquisition of this recent financing, Biogennix is well-positioned to accelerate its commercial expansion and deepen its research and development pipeline. The strategic deployment of this capital will likely focus on increasing market penetration for its core product lines while potentially exploring new indications for its TrelCor-based materials. As the company matures, the focus will shift toward sustaining long-term growth through operational excellence and the continued delivery of clinically validated, patient-centric orthopedic technologies. This late-stage momentum provides the necessary runway to solidify its leadership in the synthetic bone graft sector and navigate the complexities of the global medical device market.
See full Biogennix company page
